Literature DB >> 18022911

PIK3CA cancer mutations display gender and tissue specificity patterns.

Silvia Benvenuti1, Milo Frattini, Sabrina Arena, Carlo Zanon, Vera Cappelletti, Danila Coradini, Maria Grazia Daidone, Silvana Pilotti, Marco A Pierotti, Alberto Bardelli.   

Abstract

The occurrence of oncogenic alleles can display striking tissue specificity. For example KRAS mutations are very frequent in pancreatic cancers but relatively rare in melanomas. The opposite is true for BRAF mutations. Somatic mutations in the gene encoding for the phosphatidylinositol 3-kinase (PI3KCA) catalytic subunit, PIK3CA, occur at high frequency in many solid cancers. We have examined whether PI3K oncogenic mutations (exons 9 and 20) might exhibit gender and/or tissue specificity. By examining large cohorts of breast and colorectal cancers affecting both men and women we found that the pattern of PIK3CA mutations is distinctive. In colorectal cancers, PIK3CA (but not KRAS, APC, or TP53) mutations display a gender bias occurring at higher frequencies in women. We also found that male breast cancers display PIK3CA mutations at an overall frequency similar to that observed in female breast tumors. In male breast cancers, however, PIK3CA mutations are found mainly in exon 20. We conclude that PI3KCA mutations affecting exons 9 and 20 display gender- and tissue-specific patterns, thus suggesting that the different amino acid changes could exert distinct functional effects on the oncogenic properties of this enzyme. Furthermore, we propose that sexual dimorphisms and tissue specific factors might directly or indirectly influence the occurrence of PI3KCA cancer alleles. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022911     DOI: 10.1002/humu.20648

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

4.  The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Authors:  Shan Muhammad; Zheng Jiang; Zheng Liu; Kavanjit Kaur; Xishan Wang
Journal:  J Gastrointest Oncol       Date:  2013-03

Review 5.  Panitumumab: an arrow on target.

Authors:  László Kopper
Journal:  Pathol Oncol Res       Date:  2010-04-30       Impact factor: 3.201

6.  PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

Authors:  Mattia Barbareschi; Lucia Veronica Cuorvo; Salvatore Girlando; Emma Bragantini; Claudio Eccher; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Chiara Cantaloni; Nicola Decarli; Enzo Galligioni; Paolo Dalla Palma
Journal:  Virchows Arch       Date:  2012-06-29       Impact factor: 4.064

7.  PIK3CA mutation and methylation influences the outcome of colorectal cancer.

Authors:  Satoru Iida; Shunsuke Kato; Megumi Ishiguro; Takatoshi Matsuyama; Toshiaki Ishikawa; Hirotoshi Kobayashi; Tetsuro Higuchi; Hiroyuki Uetake; Masayuki Enomoto; Kenichi Sugihara
Journal:  Oncol Lett       Date:  2011-12-29       Impact factor: 2.967

8.  Optical measurement of rectal microvasculature as an adjunct to flexible sigmoidosocopy: gender-specific implications.

Authors:  Hemant K Roy; Andrew J Gomes; Sarah Ruderman; Laura K Bianchi; Michael J Goldberg; Valentina Stoyneva; Jeremy D Rogers; Vladimir Turzhitsky; Young Kim; Eugene Yen; Mohammed Jameel; Andrej Bogojevic; Vadim Backman
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-22

9.  The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

Authors:  Stefano Barbi; Ivana Cataldo; Giovanni De Manzoni; Samantha Bersani; Simona Lamba; Silvia Mattuzzi; Alberto Bardelli; Aldo Scarpa
Journal:  J Exp Clin Cancer Res       Date:  2010-04-16

10.  Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Authors:  Shuji Ogino; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Nadine J McCleary; Kimmie Ng; Donna Niedzwiecki; Leonard B Saltz; Robert J Mayer; Renaud Whittom; Alexander Hantel; Al B Benson; Rex B Mowat; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2013-11-14       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.